中文English
ISSN 1001-5256 (Print)
ISSN 2097-3497 (Online)
CN 22-1108/R

Drug resistance mutations in polymerase region and related influencing factors in patients with hepatitis B virus infection

DOI: 10.3969/j.issn.1001-5256.2020.06.012
Research funding:

 

  • Published Date: 2020-06-20
  • Objective To investigate the pattern of drug resistance mutations of the genes in the reverse transcriptase( RT) region and its association with clinical features in patients with hepatitis B virus( HBV) infection in Xuzhou,Jiangsu,China,as well as the influencing factors for drug resistance. Methods A total of 242 patients with HBV infection who underwent the detection of the HBV RT region in Department of Infectious Diseases,The Affiliated Hospital of Xuzhou Medical University,from May 2014 to April 2019 were enrolled,and the clinical features were compared between the patients with different genotypes and HBeAg statuses. Of all patients,164 had a clear medication history of nucleos( t) ide analogues( NAs),among whom 118 had known mutations at drug resistance loci and 46 did not have such mutations,and the risk factors for drug resistance mutations in the HBV RT region were analyzed for the two groups. The independent samples t-test or the Mann-Whitney U test was used for comparison of continuous data between groups; the chi-square test was used for comparison of categorical data between groups; a logistic regression analysis was used to investigate the risk factors for drug resistance. Results Among the patients with HBV infection in Xuzhou,rtL180 M + rtM204 I/V/S was the most common pattern of drug resistance mutation in the RT region and was observed in 25 patients( 21. 2%),followed by rtA181 T/V in 16 patients( 13. 6%) and rtM204 I/V/S in 15 patients( 12. 7%). Of all 242 patients,13( 5. 4%) had genotype B and 229( 94. 6%) had genotype C,and no other genotypes were found. The patients with genotype B had a significantly higher level of alanine aminotransferase( ALT) than those with genotype C( U =-2. 096,P =0. 036). Compared with the HBeAg-positive group,the HBeAg-negative group had a significantly older age( t = 4. 580,P < 0. 001) and significantly lower HBV DNA load and HBs Ag level( t = 2. 145 and 3. 526,P = 0. 033 and 0. 001). The HBe Ag-negative group had a significantly longer course of disease and a significantly higher level of gamma-glutamyl transpeptidase( GGT) than the HBe Ag-positive group( U =-2. 561 and-2. 016,P = 0. 010 and 0. 044). Compared with the HBe Ag-positive group,the HBe Ag-negative group had a significantly lower proportion of patients with chronic hepatitis B and a significantly higher proportion of patients with liver cirrhosis or hepatocellular carcinoma( χ2= 20. 609,P < 0. 001). The multivariate logistic regression analysis showed that administration of lamivudine + adefovir dipivoxil( OR = 0. 080,95% CI: 0. 008-0. 748,P < 0. 05),administration of adefovir dipivoxil( OR = 5. 493,95% CI: 1. 377-21. 909,P < 0. 05),and improper drug withdrawal( OR = 5. 945,95% CI: 1. 921-18. 403,P < 0. 05) were independent risk factors for drug resistance in patients with HBV infection. Conclusion Most of the patients with HBV infection in Xuzhou are infected with HBV genotype C,with a complex and diverse pattern of drug resistance mutations. HBV DNA replication is active in HBe Ag-positive patients,and therefore,it is recommended to initially select antiviral drugs with high efficiency and low resistance and strengthen the compliance with antiviral therapy.

     

  • [1] CALIGIURI P,CERRUTI R,ICARDI G,et al. Overview of hepatitis B virus mutations and their implications in the management of infection[J]. World J Gastroenterol,2016,22(1):145-154.
    [2] SONG JE,LEE CH,KIM BS. Efficacy of long-term tenofovir disoproxil fumarate therapy in chronic hepatitis B patients with partial virologic response in real practice[J]. Korean J Intern Med,2019,34(4):802-810.
    [3] Chinese Society of Infectious Disease,Chinese Medical Association; Chinese Society of Hepatology,Chinese Medical Association. Guidelines for the prevention and treatment of chronic hepatitis B(version 2019)[J]. J Clin Hepatol,2019,35(12):2648-2669.(in Chinese)中华医学会感染病学分会,中华医学会肝病学分会.慢性乙型肝炎防治指南(2019年版)[J].临床肝胆病杂志,2019,35(12):2648-2669.
    [4] MANTOVANI N,CICERO M,SANTANA LC,et al. Detection of lamivudine-resistant variants and mutations related to reduced antigenicity of HBsAg in individuals from the cities of Santos and So Paulo,Brazil[J]. Virol J,2013,10:320.
    [5] ORLANDO R,TOSONE G,PORTELLA G,et al. Prolonged persistence of lamivudine-resistant mutant and emergence of new lamivudine-resistant mutants two years after lamivudine withdrawal in HBs Ag-positive chronic hepatitis patient:A case report[J]. Infection,2008,36(5):472-474.
    [6] Chinese Society of Hepatology and Chinese Society of Infectious Diseases Chinese,Medical Association. The guideline of prevention and treatment for chronic hepatitis B:A 2015 update[J]. J Clin Hepatol,2015,31(12):1941-1960.(in Chinese)中华医学会肝病学分会,中华医学会感染病学分会.慢性乙型肝炎防治指南(2015年更新版)[J].临床肝胆病杂志,2015,31(12):1941-1960.
    [7] JIANG M,GONG X,XIAO XQ,et al. Expression of serum miRNA-122-3p in patients with CHB treated with PEG-interferon-alpha 2b[J]. Int J Virol,2019,26(5):293-298.(in Chinese)蒋敏,龚兴,肖新强,等.血清miRNA-122-3p在聚乙二醇干扰素-α2b治疗CHB患者中表达的研究[J].国际病毒学杂志,2019,26(5):293-298.
    [8] ZHANG HY,LIU LG,YE CY,et al. Evolution of drug-resistant mutations in HBV genomes in patients with treatment failure during the past seven years(2010-2016)[J]. Virus Genes,2018,54(1):41-47.
    [9] QIAN F,QIN J,LI D,et al. Monitoring of genotypic resistance profile in chronic hepatitis B patients receiving nucleos(t)ide analogues in Huzhou,China[J]. J Infect Dev Ctries,2016,10(9):996-1002.
    [10] Experts Attending the Disscussion on Hepatitis B Virus Drug Resistance. Drug resistance to nucleoside and nucleotide analogs in chronic hepatitis B and its management[J]. J ClinHepatol,2013,29(1):10-17.(in Chinese)参加乙型肝炎耐药讨论会专家.核苷和核苷酸类药物治疗慢性乙型肝炎的耐药及其管理[J].临床肝胆病杂志,2013,29(1):10-17.
    [11] LIU Y,ZHOU Y,LI X,et al. Hepatitis B virus mutation pattern rt L180M+A181C+M204V may contribute to entecavir resistance in clinical practice[J]. Emerg Microbes Infect,2019,8(1):354-365.
    [12] LEE CI,KWON SY,KIM JH,et al. Efficacy and safety of tenofovir-based rescue therapy for chronic hepatitis B patients with previous nucleo(s/t)ide treatment failure[J]. Gut Liver,2014,8(1):64-69.
    [13] SVAROVSKAIA ES,CURTIS M,ZHU Y,et al. Hepatitis B virus wild-type and rt N236T populations show similar early HBV DNA decline in adefovir refractory patients on a tenofovirbased regimen[J]. J Viral Hepat,2013,20(2):131-140.
    [14] YEH CT,CHEN T,HSU CW,et al. Emergence of the rt A181T/s W172*mutant increased the risk of hepatoma occurrence in patients with lamivudine-resistant chronic hepatitis B[J]. BMC Cancer,2011,11:398.
    [15] TERRAULT NA,LOK A,MCMAHON BJ,et al. Update on prevention,diagnosis, and treatment of chronic hepatitis B:AASLD 2018 hepatitis B guidance[J]. Hepatology,2018,67(4):1560-1599.
    [16] European Association for the Study of the Liver,European Association for the Study of the Liver. EASL 2017 Clinical Practice Guidelines on the management of hepatitis B virus infection[J]. J Hepatol,2017,67(2):370-398.
    [17] LIVINGSTON SE,SIMONETTI JP,MCMAHON BJ,et al. Hepatitis B virus genotypes in Alaska Native people with hepatocellular carcinoma:Preponderance of genotype F[J]. J Infect Dis,2007,195(1):5-11.
    [18] WANG LP,CHENG X,LI CY,et al. Relationship between pre-existing resistance mutations and HBV genotype in patients with HBV related liver cirrhosis[J]. World Chin J Dig,2017,25(10):891-896.(in Chinese)汪莉萍,程笑,李春杨,等.乙型肝炎肝硬化患者HBV预存耐药变异与基因型的关系[J].世界华人消化杂志,2017,25(10):891-896.
    [19] BAO T,HU QG,YE J,et al. Value of HBs Ag level in dynamic monitoring of disease progression in patients with chronic HBV infection[J]. J Clin Hepatol,2017,33(8):1475-1478.(in Chinese)鲍腾,胡庆刚,叶珺,等.HBsAg水平在慢性HBV感染者疾病进展中的动态监测价值[J].临床肝胆病杂志,2017,33(8):1475-1478.
    [20] HU GF,LI XP,WU ZP,et al. Clinical features of acute-onchronic liver failure induced by withdrawl of nucleos(t)ide analogues[J]. J Clin Hepatol,2017,33(7):1320-1323.(in Chinese)胡高飞,李小鹏,吴振平,等.停用核苷和核苷酸类药物抗HBV后诱发慢加急性肝衰竭的临床特征[J].临床肝胆病杂志,2017,33(7):1320-1323.
    [21] HA NB,HA NB,GARCIA RT,et al. Medication nonadherence with long-term management of patients with hepatitis B e antigen-negative chronic hepatitis B[J]. Dig Dis Sci,2011,56(8):2423-2431.
    [22] LEE HW,PARK JY,LEE JW,et al. Long-term efficacy of tenofovir disoproxil fumarate monotherapy for multidrug-resistant chronic HBV infection[J]. Clin Gastroenterol Hepatol,2019,17(7):1348-1355. e2.
    [23] LIM YS,GWAK GY,CHOI J,et al. Monotherapy with tenofovir disoproxil fumarate for adefovir-resistant vs. entecavir-resistant chronic hepatitis B:A 5-year clinical trial[J]. J Hepatol,2019,71(1):35-44.
    [24] SHIRVANI-DASTGERDI E,WINER BY,CELI-TERRASSA T,et al. Selection of the highly replicative and partially multidrug resistant rt S78T HBV polymerase mutation during TDF-ETV combination therapy[J]. J Hepatol,2017,67(2):246-254.
  • Relative Articles

    [1]Lixian WU, Weiqiang ZHENG, Huanqin HAN. Effect of different antiviral drugs in reducing the risk of hepatitis B virus-related hepatocellular carcinoma[J]. Journal of Clinical Hepatology, 2022, 38(5): 1165-1168. doi: 10.3969/j.issn.1001-5256.2022.05.040
    [2]Mingyang FENG, Hui WANG. Selection of antiviral drugs for patients with hepatitis B virus-associated hepatocellular carcinoma[J]. Journal of Clinical Hepatology, 2022, 38(11): 2452-2456. doi: 10.3969/j.issn.1001-5256.2022.11.004
    [3]Jing LI, Yu CAO, Yongmei FENG, Yuanqiang GUO, Bei JIANG, Chunyan WANG. HBV RNA level in patients with HBV-related hepatocellular carcinoma after long-term antiviral therapy with nucleos(t)ide analogues and its clinical significance[J]. Journal of Clinical Hepatology, 2021, 37(10): 2324-2326. doi: 10.3969/j.issn.1001-5256.2021.10.013
    [4]CHEN HongYu, XU XiaoYuan. Drug resistance of direct-acting antivirals in genotype 2/3 hepatitis C virus[J]. Journal of Clinical Hepatology, 2020, 36(11): 2553-2556. doi: 10.3969/j.issn.1001-5256.2020.11.035
    [5]You GuoQiong, Wang Li, Duan Meng, Zhu Peng. Research advances in direct-acting antiviral agents in the treatment of hepatitis C virus-related liver cirrhosis[J]. Journal of Clinical Hepatology, 2019, 35(1): 187-190. doi: 10.3969/j.issn.1001-5256.2019.01.041
    [6]Ning HuiBin, Liu JunPing, Jin HuiMing, Li Kuan, Xiao ErHui, Shang Jia. Direct-acting antiviral durgs for hepatitis C in children: A case report[J]. Journal of Clinical Hepatology, 2019, 35(1): 164-165. doi: 10.3969/j.issn.1001-5256.2019.01.032
    [7]Zhang JieBing, Guo HongHua. Research advances in hepatitis B cirrhosis with renal injury and the application of antiviral drugs[J]. Journal of Clinical Hepatology, 2019, 35(1): 191-196. doi: 10.3969/j.issn.1001-5256.2019.01.042
    [8]Wang MengLan, Tang Hong. Drug-drug interaction of direct-acting antivirals in treatment of chronic hepatitis C[J]. Journal of Clinical Hepatology, 2018, 34(2): 229-232. doi: 10.3969/j.issn.1001-5256.2018.02.002
    [9]Wang HuiJuan, Duan ZhongPing, Zhang HuanHu, Ren Feng. Research advances in the application of antiviral drugs during pregnancy for blocking mother-to-child transmission of hepatitis B virus[J]. Journal of Clinical Hepatology, 2018, 34(10): 2208-2212. doi: 10.3969/j.issn.1001-5256.2018.10.032
    [10]Zhang Xi, Li YongGuo. Current status of the application of direct-acting antiviral agents in treatment of chronic hepatitis C and existing problems[J]. Journal of Clinical Hepatology, 2018, 34(4): 853-857. doi: 10.3969/j.issn.1001-5256.2018.04.034
    [11]Zhao XiTai, Nie QingHe. Adverse effects, drug interactions, and safety of direct-acting antiviral agents in treatment of hepatitis C[J]. Journal of Clinical Hepatology, 2017, 33(6): 1067-1074. doi: 10.3969/j.issn.1001-5256.2017.06.010
    [12]Wang Cheng, Liao JiaJie. Treatment of HBV/HCV co-infected patients in DAA era[J]. Journal of Clinical Hepatology, 2017, 33(6): 1011-1016. doi: 10.3969/j.issn.1001-5256.2017.06.001
    [13]Ceng Qun, Jie ShengHua. Research advances in antiviral drugs and their treatment regimens in chronic hepatitis C[J]. Journal of Clinical Hepatology, 2017, 33(11): 2200-2204. doi: 10.3969/j.issn.1001-5256.2017.11.033
    [14]Bian DanDan, Zheng SuJun. Influencing factors for the therapeutic effect of direct-acting antiviral agents in hepatitis C[J]. Journal of Clinical Hepatology, 2017, 33(11): 2205-2208. doi: 10.3969/j.issn.1001-5256.2017.11.034
    [15]Chen XinYue, Liu YaLi, Ren Shan. Value of direct-acting antivirals combined with PR regimen (PEG-IFN combined with ribavirin) in the new era of antiviral therapy for hepatitis C[J]. Journal of Clinical Hepatology, 2017, 33(6): 1063-1066. doi: 10.3969/j.issn.1001-5256.2017.06.009
    [16]Wen XiaoYu, Niu JunQi. Mechanism of action of direct-acting antiviral agents in treatment of chronic hepatitis C[J]. Journal of Clinical Hepatology, 2016, 32(9): 1699-1705. doi: 10.3969/j.issn.1001-5256.2016.09.013
    [17]Zhang Yu, Cao Ying, Zhang RenWen, Zhang XiaXia, Lu HaiYing, Wu ChiHong, Huo Na, Yu Min, Liu Dan, Xu XiaoYuan. Natural resistance mutations to direct- acting antiviral agents in interferon / ribavirin treatment- experienced and treatment- nave patients with chronic hepatitis C in Beijing,China[J]. Journal of Clinical Hepatology, 2016, 32(4): 711-715. doi: 10.3969/j.issn.1001-5256.2016.04.020
    [18]Zhang Jing, Liu XueMin, Liu ZhengWen, Lu: Yi. Application of direct-acting antiviral agents in perioperative period of liver transplantation for patients with hepatitis C[J]. Journal of Clinical Hepatology, 2015, 31(12): 2084-2087. doi: 10.3969/j.issn.1001-5256.2015.12.023
    [19]Ren Shan, Chen XinYue. Current research on hepatitis C virus resistance to direct-acting antiviral agents[J]. Journal of Clinical Hepatology, 2015, 31(11): 1807-1812. doi: 10.3969/j.issn.1001-5256.2015.11.010
    [20]Deng Le, Wen ZhiLi. Review of recent research progress in correlating HBV genotypes with efficacy of antiviral treatments[J]. Journal of Clinical Hepatology, 2012, 28(6): 469-473.
  • Cited by

    Periodical cited type(1)

    1. 陈红,刘庆丰,张要锋,李慧,吕丹,李婷. Lam和TDF治疗乙肝患者病毒耐药基因研究. 实验与检验医学. 2021(03): 555-558+562 .

    Other cited types(0)

  • 加载中

Catalog

    通讯作者: 陈斌, bchen63@163.com
    • 1. 

      沈阳化工大学材料科学与工程学院 沈阳 110142

    1. 本站搜索
    2. 百度学术搜索
    3. 万方数据库搜索
    4. CNKI搜索

    Article Metrics

    Article views (1202) PDF downloads(169) Cited by(1)
    Proportional views
    Related

    /

    DownLoad:  Full-Size Img  PowerPoint
    Return
    Return